source
- Verastem makes its stand as a RevMed competitor in pancreatic cancerVerastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massac…
- Roche signs $1 billion deal with China’s Rona Therapeutics for RNAi obesity drugRoche announced a new agreement with Chinese biotech Rona Therapeutics to acquire an experimental RNA interference therapy targeting the protein ALK7 for obesity. Under the terms, Roche will pay $…